Key Drivers
- High cash / low debt
- Severe operating losses
- Extremely rich valuation
AIAI Summary
ACLX has effectively become an M&A/arbitrage trade—its upside is capped by Gilead's $115 cash offer plus a $5 CVR, so investors should treat it as an event‑driven position and focus on deal‑close probability, litigation risk, and CVR milestone odds rather than standalone biotech growth metrics.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash / low debt
- •Severe operating losses
- •Extremely rich valuation
ACLX has strong liquidity and low leverage but is suffering heavy cash burn and persistent operating losses while trading at a steep premium to current revenue and earnings.
Price Behavior
Key Price Behavior Insights:
- •Large gap-up
- •Tight consolidation
- •Slightly higher highs
ACLX shows a one‑time, large gap up in the last month (from $64.11 to $113.75) followed by a narrow, slightly upward consolidation that signals acceptance of the new price level;
Sharp gap from $64.11 on 2026-02-20 to $113.75 on 2026-02-23
Sentiment & News
Key News Insights:
- •Large premium
- •Legal scrutiny
- •Insider selling
Gilead's $115/share plus $5 CVR acquisition of Arcellx (~$7.8B) sent ACLX up ~75–80% premarket and prompted multiple investor lawsuits and probes amid insider-selling reports and lukewarm analyst sentiment.
ACLX is likely to remain volatile with upside capped by deal-close risks as litigation and regulatory reviews could delay or reshape transaction terms
Similar Companies in Healthcare
Other companies in the same sector with AI ratings